Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
All articles by Steve Duffy
Treatment for Severe Malaria Receives Breakthrough Therapy Status
The Food and Drug Administration has granted an investigational treatment for severe malaria Breakthrough Therapy designation.
FDA to Review Baloxavir sNDA for Patients at High-Risk for Flu Complications
The Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil; Genentech) for the treatment of influenza in patients at high risk of complications.
Next post in Influenza
